Références
Yerly P, Vachiéry JL (2011) Anorexigènes et maladies cardiovasculaires: les liaisons dangereuses. Réanimation 20:424–435
Abenhaim L, Moride Y, Brenot F, et al (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 335:609–616
Jick H, Vasilakis C, Weinrauch LA, et al (1998) A populationbased study of appetite-suppressant drugs and the risk of cardiacvalve regurgitation. N Engl J Med 339:719–724
Jollis JG, Landolfo CK, Kisslo J, et al (2000) Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 101:2071–2077
Hill C (2011) Number of deaths attributable to benfluorex. Presse Med 40:462–469
Weill A, Païta M, Tuppin P, et al (2010) Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 19:1256–1262
Références
Abenhaim L, Moride Y, Brenot F, et al (1996) Appetitesuppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 335:609–616
Delcroix M, Kurz X, Walckiers D, et al (1998) High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium. Eur Respir J 12:271–276
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hill, C., Frachon, I. Lettre à L’éditeur. Réanimation 21, 119–121 (2012). https://doi.org/10.1007/s13546-012-0443-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13546-012-0443-8